 Oxford Immunotec Global PLC OXFD the Company, a global, high-growth diagnostics company, today announces two ground-breaking publications in Clinical Infectious Diseases CID on the performance of T-SPOT.CMV; a test for measuring the strength of a patients cellular immune response to Cytomegalovirus CMV in kidney and stem cell transplant. Increased response in the T-SPOT.CMV test is associated with protection against CMV infection. Application of the test raises the prospect of improved, individualized management of CMV infection risk in transplant recipients. 